FAS and hepatocellular carcinoma: When we considered PTEN loss in combination with FAS overexpression, HCC patients with PTEN loss plus FAS overexpression had significantly worse prognosis than other patients (p = 0.011; Figure 4b); survival rates were 0% and 51%, respectively, and median survival times were 8.5 and 32 months, respectively.